Turtle Technology was founded with the aim of introducing globally competitive products and technical services through the innovative fusion of chip technology, including microfluidic chip technology, with life sciences and precision medicine. Committed to leading life science and molecular diagnostics into the digital era, Turtle Technology has successively obtained approval as the National Genetic Testing Technology Application Demonstration Center and the nation's first Digital PCR Metrological Evaluation Certificate. We have launched a variety of digital PCR systems, achieving comprehensive innovation in genetic testing instruments, chip consumables, Ultra-Multiplex reagents, and ultra-high specificity molecular diagnostic polymerase. Turtle Technology has evolved into a high-tech enterprise integrating research and development, production, sales, and services. Our vision is to contribute to everyone's precise health through continuous innovation and breakthroughs in technology and products.

You mentioned life science and molecular diagnostics earlier. Could you elaborate on the specific focus areas and progress of the company?

Turtle Technology focuses on medical diagnostics and life sciences, aiming to lead life science and molecular diagnostics into the digital era. Since its inception, the company has been primarily engaged in research and development. It became one of China's first enterprises dedicated to semiconductor gene sequencing and digital PCR development, based on the independently innovated microfluidic chip technology. Within two years, the company completed small-scale production of semiconductor high-throughput gene sequencing chips and the prototype of a semiconductor gene sequencer with matching sequencing reagents. Soon after, we developed and released the first generation of digital PCR instruments in China. In 2019, Turtle Technology focused on the digital PCR field, releasing the BioDigital·Qing combo machines and obtaining a medical device registration certificate. In 2022, a fruitful year for Turtle Technology, we became the first Chinese company to receive the Digital PCR Metrological Evaluation Certificate and defined the Perfect-ARMS third-generation ARMS technology. Subsequently, Turtle Technology introduced the BioDigital·Yan all-in-one machine. In 2023, responding to national health policies, we launched the SCI Digital dPCR mini all-in-one machine. This product is expected to achieve large-scale popularization of digital PCR technology in medical and biological research laboratories while ensuring excellent quantitative performance, considering cost control, and emphasizing user convenience.

Focusing on Turtle Technology's products, can you discuss which areas and needs have been addressed?

Turtle Technology, with digital PCR technology as its core, released the BioDigital·Qing combo machines in 2019, obtaining a medical device registration certificate. In 2022, the BioDigital·炎 all-in-one machine was launched. In 2023, Turtle Technology responded to national health service policies by introducing the SCI Digital digital PCR mini all-in-one machine. While ensuring outstanding quantitative performance, this product also takes into account cost control and user convenience, enabling researchers to use cutting-edge technology at the lowest cost and with the simplest operation. The digital PCR product series can provide the most accurate and authoritative test data in various fields, including liquid biopsy for tumors, infectious diseases, genetic reproduction, biopharmaceuticals, food safety, inspection and quarantine, environmental microbiology testing, agriculture, forestry, animal husbandry, and fishery, as well as the determination of standard substances. Turtle Technology's latest Super-High Specificity Polymerase (SNUPP), known for its precise recognition of single-base mismatches, effectively addresses challenges in SNP and INDEL detection, gene editing detection, gene mutation detection, and tumor mutation detection.

Since its establishment, Turtle Technology has attached great importance to expanding into the international market, aiming to serve global markets with innovative technical products. Recently, Turtle Technology has established close cooperation with channels and biotechnology companies in Russia and Europe. We focus on promoting revolutionary products such as the SCI Digital mini all-in-one machine, the Super-High Specificity Polymerase (SNUPP) , and innovative Exponential Ultra-Multiplex Digital PCR Technology. Currently, Turtle Technology is further expanding into markets such as Southeast Asia, Japan, and the United States. To succeed in the international market, it is crucial to enhance our core strength while effectively promoting our products internationally.

As I mentioned earlier, Turtle Technology focuses on medical diagnostics and life sciences. Our innovative digital PCR technology products have gained recognition from a large number of customers. In the future, we will continue to develop and launch more new products in life sciences and medical diagnostics, with a focus on digital PCR. We aim to create comprehensive solutions for digital PCR and strive to become the world's top supplier. Turtle Technology will actively promote collaboration, strengthen the research and development and promotion system, and continue to research and launch more new products in life sciences and medical diagnostics, with a focus on biochips. We are also developing a large AI model vertical for life science and precision medicine, aiming to contribute to the journey of humanity in the field of precision medicine and the entire life sciences sector.